用語

 Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial  Lenze EJ, Mattar C, Zorumski CF, et al.〔JAMA. 2020 Dec 8;324(22):2292-2300〕有症状COVID-19外来患者の臨床的悪化に対するフルボキサミンの効果 ― プラセボ対照無作為化試験　（日本語概要） Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants Oskotsky T, Marić I, Tang A, et al.　〔JAMA Netw Open. 2021 Nov 1;4(11):e2133090〕抗うつ薬の選択的セロトニン再取り込み阻害薬を処方されたCOVID-19患者の死亡リスク　（日本語概要）

 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.  Cao B, et al.　〔N Engl J Med. 2020 May 7;382(19):1787-1799〕 重症COVID-19で入院中の成人患者におけるロピナビル-リトナビル試験　（日本語概要）  Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised,...

 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.  Gautret P, et al.　〔Int J Antimicrob Agents. 2020 Mar 20:105949〕 ヒドロキシクロロキンおよびアジスロマイシンによるCOVID-19の治療：オープンラベル非無作為化臨床試験の結果　（日本語概要） No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Molina JM, et al.　〔Med Mal Infect. 2020...

 Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial  Gunst JD, Staerke NB, Pahus MH, et al.　〔EClinicalMedicine. 2021 Apr 22;35:100849〕COVID-19入院患者におけるTMPRSS2阻害薬カモスタットメシル酸塩の有効性 ― 二重盲検無作為化比較試験　（日本語概要）

 The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial  Chaccour C, Casellas A, Blanco-Di Matteo A, et al.　〔EClinicalMedicine. 2021 Feb;32:100720〕非重症COVID-19患者のウイルス量，症状，液性応答に対するイベルメクチンによる早期治療の効果 ― 二重盲検プラセボ対照無作為化パイロット臨床試験　（日本語概要） Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A...